A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The Colorado House of Representatives has given its final approval to a bill that would allow a form of psilocybin to be prescribed as a medication if the federal government authorizes its use. About ...
Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...
The FDA's decision comes despite mixed results in clinical trials of the drug as an adjunctive treatment for depression. It comes on the back of a new pair of pivotal trials (RGH-MD-75 and 3111 ...
A Senate committee in Virginia has advanced legislation that would fund clinical trials involving veterans and “breakthrough therapies” as designated by the Food and Drug Administration (FDA), ...
Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback